

TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design

WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online



1.

Wilhelm, S.: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nature Reviews Drug Discovery*. 5, 835–844 (2006).
<https://doi.org/10.1038/nrd2130>.

2.

Smith, R.A.: Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. *Bioorganic & Medicinal Chemistry Letters*. 11, 2775–2778 (2001).
[https://doi.org/10.1016/S0960-894X\(01\)00571-6](https://doi.org/10.1016/S0960-894X(01)00571-6).

3.

Kola, I., Landis, J.: Opinion: Can the pharmaceutical industry reduce attrition rates? *Nature Reviews Drug Discovery*. 3, 711–716 (2004). <https://doi.org/10.1038/nrd1470>.

4.

Swinney, D.C., Anthony, J.: How were new medicines discovered? *Nature Reviews Drug Discovery*. 10, 507–519 (2011). <https://doi.org/10.1038/nrd3480>.

5.

Macarron, R., Banks, M.N., Bojanic, D., Burns, D.J., Cirovic, D.A., Garyantes, T., Green, D.V.S., Hertzberg, R.P., Janzen, W.P., Paslay, J.W., Schopfer, U., Sittampalam, G.S.: Impact of high-throughput screening in biomedical research. *Nature Reviews Drug Discovery*. 10, 188–195 (2011). <https://doi.org/10.1038/nrd3368>.

6.

Selzer, P. M., Rohwer, A., Marhöfer, R. J.: Applied bioinformatics: an introduction. Springer, Berlin (2008).

7.

Xiong, Jin: Essential bioinformatics. Cambridge University Press, New York (2006).

8.

Orengo, Christine Ann, Thornton, Janet M., Jones, David Tudor: Bioinformatics: genes, proteins and computers. BIOS, Oxford (2003).

9.

Zvelebil, Marketa J., Baum, Jeremy O.: Understanding bioinformatics. Garland Science, London (2008).

10.

Gu, Jenny, Bourne, Philip E.: Structural bioinformatics. Wiley, Hoboken, N.J. (2008).

11.

Petsko, Gregory A., Ringe, Dagmar: Protein structure and function. New Science, London (2004).

12.

Nelson, David L., Cox, Michael M., Lehninger, Albert L.: Lehninger principles of biochemistry. W.H. Freeman, Basingstoke (2008).

13.

Chandra, N.: Computational systems approach for drug target discovery. Expert Opinion on Drug Discovery. 4, 1221–1236 (2009). <https://doi.org/10.1517/17460440903380422>.

14.

Overington, J.P., Al-Lazikani, B., Hopkins, A.L.: How many drug targets are there? *Nature Reviews Drug Discovery*. 5, 993–996 (2006). <https://doi.org/10.1038/nrd2199>.

15.

Fitt, R., Nodder, E.: Setting the threshold for industrial application: the UK diverges from Europe. *Journal of Intellectual Property Law & Practice*. 5, 560–565 (2010). <https://doi.org/10.1093/jiplp/jpq061>.

16.

Ikura, M., Inouye, M.: NMR structure of the histidine kinase domain of the *E. coli*: osmosensor EnvZ : Article : *Nature*. *Nature*. 396, 88–92 (1998). <https://doi.org/10.1038/23968>.

17.

Krohn, K.A., Link, J.M.: Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. *Nuclear Medicine and Biology*. 30, 819–826 (2003). [https://doi.org/10.1016/S0969-8051\(03\)00132-X](https://doi.org/10.1016/S0969-8051(03)00132-X).

18.

Jarnagin, K.: Receptor Binding in Drug Discovery. In: eLS.

19.

Jarnagin, K.: Receptor Binding in Drug Discovery. John Wiley & Sons, Ltd, Chichester (2001). <https://doi.org/10.1038/npg.els.0000056>.

20.

Cornish-Bowden, Athel: Fundamentals of enzyme kinetics. Portland, London (2004).

21.

Copeland, Robert Allen: Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. J. Wiley, Hoboken, N.J. (2005).

22.

Gibb, Alasdair J., Foreman, John C., Johansen, Torben: Textbook of receptor pharmacology. CRC Press, Boca Raton, FL (2011).

23.

Rang, H. P., Dale, M. Maureen: Pharmacology. Churchill Livingstone, Edinburgh (2019).

24.

Colquhoun, D.: Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. British Journal of Pharmacology. 125, 923–947 (1998). <https://doi.org/10.1038/sj.bjp.0702164>.

25.

Khawaja, X., Dunlop, J., Kowal, D.: Scintillation proximity assay in lead discovery. Expert Opinion on Drug Discovery. 3, 1267–1280 (2008). <https://doi.org/10.1517/17460441.3.11.1267>.

26.

Kenakin, T.P.: Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery. 8, 617–626 (2009). <https://doi.org/10.1038/nrd2838>.

27.

Dunlop, J.: High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nature Reviews Drug Discovery. 7, 358–368 (2008). <https://doi.org/10.1038/nrd2552>.

28.

Hopkins, A.L., Groom, C.R.: Opinion: The druggable genome. *Nature Reviews Drug Discovery*. 1, 727–730 (2002). <https://doi.org/10.1038/nrd892>.

29.

Richard M. Durbin: A map of human genome variation from population-scale sequencing. *Nature*. 467, 1061–1073 (2010). <https://doi.org/10.1038/nature09534>.

30.

Thomas, Gareth: *Fundamentals of medicinal chemistry*. (2003).

31.

Patrick, Graham L.: *An introduction to medicinal chemistry*. (2017).

32.

Leach, Andrew R., Gillet, Valerie J.: *An introduction to chemoinformatics*. (2003).

33.

Engel, Thomas, Gasteiger, J.: *Chemoinformatics: a textbook*. (2003).

34.

Gasteiger, J.: *Handbook of chemoinformatics: from data to knowledge*. (2003).

35.

Bissantz, C., Kuhn, B., Stahl, M.: A Medicinal Chemist's Guide to Molecular Interactions. *Journal of Medicinal Chemistry*. 53, 5061–5084 (2010). <https://doi.org/10.1021/jm100112j>.

36.

Matter, H.: Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. *Journal of Medicinal Chemistry*. 40, 1219–1229 (1997). <https://doi.org/10.1021/jm960352+>.

37.

Willett, P., Barnard, J.M., Downs, G.M.: Chemical Similarity Searching. *Journal of Chemical Information and Modeling*. 38, 983–996 (1998). <https://doi.org/10.1021/ci9800211>.

38.

Welsch, M.E., Snyder, S.A., Stockwell, B.R.: Privileged scaffolds for library design and drug discovery. *Current Opinion in Chemical Biology*. 14, 347–361 (2010). <https://doi.org/10.1016/j.cbpa.2010.02.018>.

39.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 23, 3–25 (1997). [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1).

40.

Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W., Kopple, K.D.: Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *Journal of Medicinal Chemistry*. 45, 2615–2623 (2002). <https://doi.org/10.1021/jm020017n>.

41.

Blake, J.F.: Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate. *Medicinal Chemistry*. 1, 649–655 (2005). <https://doi.org/10.2174/157340605774598081>.

42.

Beck, A., Wurch, T., Bailly, C., Corvaia, N.: Strategies and challenges for the next generation of therapeutic antibodies. *Nature Reviews Immunology*. 10, 345–352 (2010).

<https://doi.org/10.1038/nri2747>.

43.

Bradbury, A.R.M., Sidhu, S., Dübel, S., McCafferty, J.: Beyond natural antibodies: the power of in vitro display technologies. *Nature Biotechnology*. 29, 245–254 (2011). <https://doi.org/10.1038/nbt.1791>.

44.

Nagorsen, D., Baeuerle, P.A.: Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. *Experimental Cell Research*. 317, 1255–1260 (2011). <https://doi.org/10.1016/j.yexcr.2011.03.010>.

45.

Pillay, V., Gan, H.K., Scott, A.M.: Antibodies in oncology. *New Biotechnology*. 28, 518–529 (2011). <https://doi.org/10.1016/j.nbt.2011.03.021>.

46.

Schrama, D., Reisfeld, R.A., Becker, J.C.: Antibody targeted drugs as cancer therapeutics. *Nature Reviews Drug Discovery*. 5, 147–159 (2006). <https://doi.org/10.1038/nrd1957>.

47.

Weiner, L.M., Surana, R., Wang, S.: Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nature Reviews Immunology*. 10, 317–327 (2010). <https://doi.org/10.1038/nri2744>.

48.

Ducry, L., Stump, B.: Antibody–drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. *Bioconjugate chemistry*. 21, 5–13 (2010). <https://doi.org/10.1021/bc9002019>.

49.

Alley, S.C., Okeley, N.M., Senter, P.D.: Antibody–drug conjugates: targeted drug delivery for cancer. *Current Opinion in Chemical Biology*. 14, 529–537 (2010). <https://doi.org/10.1016/j.cbpa.2010.06.170>.

50.

Webb, S.: Pharma interest surges in antibody drug conjugates. *Nature Biotechnology*. 29, 297–298 (2011). <https://doi.org/10.1038/nbt0411-297>.

51.

Holliger, P., Hudson, P.J.: Engineered antibody fragments and the rise of single domains. *Nature Biotechnology*. 23, 1126–1136 (2005). <https://doi.org/10.1038/nbt1142>.

52.

Jinek, M., Doudna, J.A.: A three-dimensional view of the molecular machinery of RNA interference. *Nature*. 457, 405–412 (2009). <https://doi.org/10.1038/nature07755>.

53.

Castanotto, D., Rossi, J.J.: The promises and pitfalls of RNA-interference-based therapeutics. *Nature*. 457, 426–433 (2009). <https://doi.org/10.1038/nature07758>.

54.

Grimm, D.: Small silencing RNAs: State-of-the-art. *Advanced Drug Delivery Reviews*. 61, 672–703 (2009). <https://doi.org/10.1016/j.addr.2009.05.002>.

55.

Vaishnaw, A.K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., Maraganore, J.: A status report on RNAi therapeutics. *Silence*. 1, (2010). <https://doi.org/10.1186/1758-907X-1-14>.

56.

Shen, J., Samul, R., Silva, R.L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S.F., Zinnen, S.,

Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., Campochiaro, P.A.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. *Gene Therapy*. 13, 225–234 (2005). <https://doi.org/10.1038/sj.gt.3302641>.

57.

Kalluri, R., Kanasaki, K.: RNA interference: Generic block on angiogenesis. *Nature*. 452, 543–545 (2008). <https://doi.org/10.1038/452543a>.

58.

Human embryonic stem cells: Derivation, culture, and differentiation: A review.

59.

Stadtfield, M., Hochedlinger, K.: Induced pluripotency: history, mechanisms, and applications. *Genes & Development*. 24, 2239–2263 (2010). <https://doi.org/10.1101/gad.1963910>.

60.

Watt, F.M., Driskell, R.R.: The therapeutic potential of stem cells. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 365, 155–163 (2010). <https://doi.org/10.1098/rstb.2009.0149>.

61.

Brignier, A.C., Gewirtz, A.M.: Embryonic and adult stem cell therapy. *Journal of Allergy and Clinical Immunology*. 125, S336–S344 (2010). <https://doi.org/10.1016/j.jaci.2009.09.032>.

62.

Lledo, P.-M., Merkle, F.T., Alvarez-Buylla, A.: Origin and function of olfactory bulb interneuron diversity. *Trends in Neurosciences*. 31, 392–400 (2008). <https://doi.org/10.1016/j.tins.2008.05.006>.

63.

Murray, C.W.: Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. *Journal of Medicinal Chemistry*. 53, 5942–5955 (2010). <https://doi.org/10.1021/jm100059d>.

64.

Hopkins, A.L., Groom, C.R., Alex, A.: Ligand efficiency: a useful metric for lead selection. *Drug Discovery Today*. 9, 430–431 (2004). [https://doi.org/10.1016/S1359-6446\(04\)03069-7](https://doi.org/10.1016/S1359-6446(04)03069-7).

65.

Congreve, M., Chessari, G., Tisi, D., Woodhead, A.J.: Recent Developments in Fragment-Based Drug Discovery. *Journal of Medicinal Chemistry*. 51, 3661–3680 (2008). <https://doi.org/10.1021/jm8000373>.

66.

Murray, C.W., Rees, D.C.: The rise of fragment-based drug discovery. *Nature Chemistry*. 1, 187–192 (2009). <https://doi.org/10.1038/nchem.217>.

67.

Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., Finch, H., Fromont, C., Richardson, C., Simmonite, H., Hubbard, R.E.: Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. *Journal of Chemical Information and Modeling*. 44, 2157–2166 (2004). <https://doi.org/10.1021/ci049806z>.

68.

Woodhead, A.J.: Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. *Journal of Medicinal Chemistry*. 53, 5956–5969 (2010). <https://doi.org/10.1021/jm100060b>.

69.

DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug

development costs. *Journal of Health Economics*. 22, 151–185 (2003).
[https://doi.org/10.1016/S0167-6296\(02\)00126-1](https://doi.org/10.1016/S0167-6296(02)00126-1).